Mesembrine-Derived Alkaloid Compounds for Selective PDE4 Inhibition
Solution Overview
Problem
Existing therapeutic compounds derived from Sceletium plants, such as mesembrine and mesembrenone, face challenges due to variability and instability in natural extract content, as well as undesirable pharmacokinetic profiles, leading to side effects like nausea and emesis when used as PDE4 inhibitors for treating depression and anxiety.
Innovation Solution
Development of novel alkaloid compounds, represented by Formulas (IA) and (IB), which are designed to selectively inhibit PDE4 enzymes while minimizing side effects, with specific substitutions for R1, R2, R3, and m, and optionally forming heterocycloalkyl or heteroaryl groups with Ra and Rb, to enhance stability and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If natural alkaloid compounds (mesembrine and mesembrenone) are used as PDE4 inhibitors, then therapeutic effects for depression and anxiety are achieved, but side effects such as nausea and emesis occur
Solution Approach 1:
The patent applies parameter changes by systematically modifying the chemical structure of natural alkaloids through various substitutions (R1-R6 groups, oxidation states, stereochemistry) to create analogs with improved side effect profiles while maintaining PDE4 inhibitory activity. This includes changing functional groups, ring structures, and molecular weight parameters to optimize the therapeutic window.
Solution Approach 2:
The patent creates synthetic copies and analogs of the natural alkaloids mesembrine and mesembrenone. Rather than using the natural compounds directly, synthetic versions with modified structures are developed to replicate the therapeutic benefits while eliminating the harmful side effects associated with the natural products.
2Reliability
If natural extracts from Sceletium plants are used, then therapeutic compounds are obtained, but variability and instability in compound content occur
Solution Approach 1:
Instead of relying on natural extracts with variable composition, the patent creates synthetic copies of the active alkaloid compounds. This ensures consistent, reproducible supply of therapeutically active ingredients with controlled purity and stability, eliminating the batch-to-batch variability inherent in plant extracts.
Solution Approach 2:
The patent systematically varies structural parameters (substituents, oxidation states, stereochemistry) to identify and optimize stable analogs. This allows selection of compounds with improved metabolic stability, solubility, and storage characteristics compared to the natural alkaloids.
3Reliability
If higher doses of PDE4 inhibitors are administered, then central function and therapeutic effects are enhanced, but mechanism-related side effects increase
Solution Approach 1:
The patent modifies molecular parameters (lipophilicity, molecular weight, functional groups) to optimize brain penetration and PDE4 selectivity. This allows achievement of therapeutic effects at lower doses, reducing the incidence of mechanism-related side effects that occur with higher dosing of conventional PDE4 inhibitors.
Solution Approach 2:
The patent introduces selective structural features (specific substituents at particular positions, stereochemical configurations) that enhance selectivity for CNS PDE4 isoforms over other PDE isoforms. This local optimization of molecular properties ensures preferential action in the central nervous system at lower doses, minimizing peripheral side effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds provide effective treatment for depression and anxiety by inhibiting PDE4 enzymes with reduced side effects, offering improved pharmacokinetic profiles and stability compared to natural alkaloids.
Implementation Method 1
Phosphodiesterase-4 (PDE-4) enzymes hydrolyze the cyclic nucleotide intracellular second messengers (cAMP and cGMP), leading to inactivation or inhibition of these enzymes and resulting in elevated levels of cAMP and cGMP in the cell
Implementation Method 2
Certain bioactive indole alkaloid compounds obtained from plants of the genus Sceletium, such as mesembrine and mesembrenone, can inhibit serotonin (5-HT) uptake and phosphodiesterase-4 (PDE-4)
Data Source
AI summary
Disclosed are compounds that are derivatives of mesembrine or mesembrenone, and related methods of preparing and using these compounds.